Selux Diagnostics develops the Selux Next Generation Phenotyping (NGP) System, a rapid antibiotic susceptibility testing (AST) platform that can deliver same-day AST results. The company says the platform can provide single-platform rapid AST for both positive blood culture and isolated colonies following its third FDA 510(k) clearance on the direct-from-Positive Blood Culture Separator. Selux intends to use the additional funding to launch the next phase of commercialization of the NGP System within the United States. The company is led by CEO Steve Lufkin and aims to accelerate selection of personalized antimicrobial therapy for infectious disease patients to reduce overreliance on broad-spectrum antibiotics. The NGP program has been supported in whole or in part with federal funds from HHS, ASPR, and BARDA under contract HHSO100201800013C. Selux Diagnostics is focused on accelerating antibiotic susceptibility testing (AST) with its proprietary Next-Generation Phenotyping (NGP) platform to deliver actionable results days faster than current standards. The NGP platform aims to enable clinicians to provide personalized antimicrobial therapies within 24 hours, improving patient outcomes and reducing broad-spectrum antibiotic overuse. Selux describes the platform as meeting accuracy, throughput, and cost-effectiveness requirements of clinical microbiology laboratories and integrated healthcare systems. The platform is an investigational device and the company is working with BARDA and other private investors to advance development. Selux says the work addresses the urgent global threat of antimicrobial resistance and is funded in part by federal BARDA/ASPR/HHS support. The company is Boston-based and described as five years old in the announcement. Selux Diagnostics is a Boston-based medical device company developing the Next-Generation Phenotyping (NGP) rapid antimicrobial susceptibility testing platform. The NGP platform provides <24-hour personalized antimicrobial therapy results and enables same-shift susceptibility testing of up to 50 antibiotics in parallel through a high-throughput, fully automated system. Selux's platform combines novel biochemical assays with artificial intelligence to differentiate antibiotic-induced bacterial growth modes and accelerate targeted patient therapies. The company says proceeds from its recent financing will fund commercialization of NGP as it seeks to establish same-shift rapid AST as the new standard. Selux is five years old and positions its technology to shorten hospital stays, improve patient outcomes, and help combat antibiotic resistance. CEO Steve Lufkin described the partnership with Oxford as the next step in fighting the global crisis of antibiotic resistance. Selux Diagnostics develops a Phenotyping (NGP) rapid antimicrobial susceptibility testing platform that delivers automated AST results and enables same-shift susceptibility testing of up to 50 antibiotics in parallel. The platform combines novel biochemical assays and artificial intelligence to differentiate antibiotic-induced bacterial growth modes. Selux aims to fast-track targeted patient therapies so patients can receive appropriate treatments on day one. The company is led by CEO Steve Lufkin and is based in Boston, MA. Selux has regulatory progress including FDA Breakthrough Device Designation for NGP in September 2021 for positive blood culture and sterile body fluid indications, and received a $2.8M NIH award in October 2021 to support commercialization. The company plans to use new funding to support the U.S. commercial launch of NGP. Selux Diagnostics is developing the Next-Generation Phenotyping (NGP) platform for rapid antimicrobial susceptibility testing (AST) that aims to provide targeted therapy results in under 24 hours. The proprietary NGP technology delivers rapid AST results from cultured isolates with a broad antibiotic menu while targeting the accuracy, throughput, and cost-effectiveness required by clinical microbiology laboratories and integrated healthcare systems. Selux completed its first clinical trial, which confirmed the platform's ability to accurately provide rapid AST within the same shift, and the company plans to submit those results to the U.S. Food and Drug Administration as the next step toward commercialization. The platform is investigational and has been funded in whole or in part by BARDA under Contract No. HHSO100201800013C. Selux says it will use the funding to continue implementing its microbiology roadmap and accelerate product development to speed time to targeted antibiotic treatment. The five-year-old company is based in Boston, MA.

Total raised

$162M

Funding rounds

6

Latest round

Equity

Latest activity

Apr 2024